The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts

Sylvia Cruchet, Raquel Furnes, Aldo Maruy, Eduardo Hebel, Jorge Palacios, Fernando Medina, Nelson Ramirez, Marina Orsi, Lysette Rondon, Vera Sdepanian, Luis Xóchihua, Manuel Ybarra, Roberto Arturo Zablah, Sylvia Cruchet, Raquel Furnes, Aldo Maruy, Eduardo Hebel, Jorge Palacios, Fernando Medina, Nelson Ramirez, Marina Orsi, Lysette Rondon, Vera Sdepanian, Luis Xóchihua, Manuel Ybarra, Roberto Arturo Zablah

Abstract

Objective: The stability and composition of intestinal flora plays a vital role in human wellbeing throughout life from as early as birth. Over the past 50 years, several studies have been conducted to evaluate the effect of probiotic administration in pediatric gastroenterology. This document aims to provide a recommendation score on probiotic utilization in pediatric gastroenterology, together with a review of current knowledge concerning its benefits, tolerability, and safety.

Study design: Published literature was selected without study design restriction: clinical guidelines, meta-analyses, randomized controlled trials (RCTs), cohort studies, outcomes research and case-controlled studies were selected using the following MESH-validated terms: probiotics, diarrhea, acute diarrhea, antibiotic-associated diarrhea, traveler's diarrhea, bacterial diarrhea, nosocomial diarrhea, prophylactic diarrhea, Helicobacter pylori infection, colic, infantile colic, necrotizing enterocolitis (NEC), inflammatory bowel disease, constipation, and allergy. Once the validity and the quality of results were evaluated, a recommendation score and level of evidence were assigned for pediatric gastrointestinal-related conditions, according to the updated Evidence-Based Medicine guidelines: 1a for systematic review (SR) of RCTs, 1b for individual RCT, 1c for SR and individual RCT, 2a for SR of cohort studies, 2b for individual cohort studies, 2c for outcomes research, and 3a for SR of case-control studies.

Results and conclusions: The Latin American Expert group consensus recommends the use of the following probiotics for pediatric gastrointestinal conditions: prevention of acute infectious diarrhea (AID): 1b for Bifidobacterium lactis, Lactobacillus rhamnosus GG (LGG), and L. reuteri; prevention of nosocomial diarrhea: 1 b for B. lactis Bb12, B. bifidum, LGG and Streptococcus thermophiles; treatment of AID: 1a for LGG and S. boulardii, 1b for L. reuteri; prevention of antibiotic-associated diarrhea: 1b for LGG and S. boulardii; prevention of traveler's diarrhea: 1b for S. boulardii; prevention of infantile colic: 1a for L. reuteri DSM 17938; treatment of infantile colic: 1b for L. reuteri DSM 17938; prevention of NEC: 1a for B. breve, mixtures of Bifidobacterium and Streptococcus, LGG, L. acidophilus and L. reuteri DSM 17938; induction and maintenance of remission in ulcerative colitis: 1b for VSL#3; improving symptoms of irritable bowel syndrome: 2c for LGG and VSL#3.

Figures

Fig. 1
Fig. 1
Flow chart showing papers identified and evaluated for this review

References

    1. Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
    1. Jaeschke R, et al. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1994;271:389–391.
    1. Laupacis A, et al. Users’ guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA. 1994;272:234–237.
    1. Levine M, et al. Users’ guides to the medical literature. IV. How to use an article about harm. Evidence-Based Medicine Working Group. JAMA. 1994;271:1615–1619.
    1. Oxman AD, et al. Users’ guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. JAMA. 1994;272:1367–1371.
    1. CEBM. Oxford Centre for Evidence-Based Medicine—levels of evidence. Centre for Evidence-Based Medicine. 2009. . Accessed 15 July 2014.
    1. FAO/WHO. Working group on drafting guidelines for the evaluation of probiotics in food. Guidelines for the evaluation of probiotics in food. 2002. . Accessed 2 Sept 2010.
    1. Huff BA. Caveat emptor. “Probiotics” might not be what they seem. Can Fam Physician. 2004;50:583–587.
    1. Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science. 1965;147:747–748.
    1. Parker RB. Probiotics, the other half of the antibiotic story. Animal Nutr Health. 1974;29:4–8.
    1. Tissier H. Tritement des infections intestinales par la methode de translormation de la flore bacterienne de l’intestin. C R Soc Biol. 1906;60:359–361.
    1. FAO/WHO. Joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food. 2001. . Accessed 2 Sept 2010.
    1. Czerucka D, et al. Review article: yeast as probiotics—Saccharomyces boulardii. Aliment Pharmacol Ther. 2007;26:767–778.
    1. Lajolo F. Alimentos funcionales: Aspectos Científicos y Regulatorios. Dieta y Salud. 2003;10:2–7.
    1. ANMAT. Alimentos Funcionales Probióticos. 2010. . Accessed 30 Oct 2014.
    1. Elmer GW, et al. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA. 1996;275:870–876.
    1. Gorbach SL. Prebióticos y lácteos fermentados: sus beneficios para la salud. Infect Dis Clin Pract Esp. 1995;3:2–7.
    1. Henriquez Moya M, Moreno C. Probióticos: Legislación en Marcha. Dirección Nacional de Alimentos. Secretaria de Agricultura, Ganadería, Pesca y Alimentos. 2009. . Accessed 2 Sept 2010.
    1. WGO. Probióticos y Prebióticos. World Gastroenterology Organisation. 2008. . Accessed 2 Sept 2010.
    1. Borchers AT, et al. Probiotics and immunity. J Gastroenterol. 2009;44:26–46.
    1. Indriyani S. Effects of live versus heat-killed probiotics on acute diarrhea in young children. Indriyani Paediatr Indones. 2012;52:249–254.
    1. Chen X, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem. 2006;281:24449–24454.
    1. Lutgendorff F, et al. The role of microbiota and probiotics in stress-induced gastro-intestinal damage. Curr Mol Med. 2008;8:282–298.
    1. Donkor ON, et al. Cytokine profile and induction of T helper type 17 and regulatory T cells by human peripheral mononuclear cells after microbial exposure. Clin Exp Immunol. 2012;167:282–295.
    1. Guarino A, et al. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol. 2009;25:18–23.
    1. Kaila M, et al. A prospective study of humoral immune responses to cow milk antigens in the first year of life. Pediatr Allergy Immunol. 1994;5:164–169.
    1. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16:2202–2222.
    1. Saran S, et al. Use of fermented foods to combat stunting and failure to thrive. Nutrition. 2002;18:393–396.
    1. Sazawal S, et al. Efficacy of milk fortified with a probiotic Bifidobacterium lactis (DR-10TM) and prebiotic galacto-oligosaccharides in prevention of morbidity and on nutritional status. Asia Pac J Clin Nutr. 2004;13:S28.
    1. Agostoni C, et al. Probiotic bacteria in dietetic products for infants: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2004;38:365–374.
    1. Szajewska H, et al. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr. 2006;42:454–475.
    1. Saavedra JM, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994;344:1046–1049.
    1. Szajewska H, et al. Efficacy of LactobacillusGG in prevention of nosocomial diarrhea in infants. J Pediatr. 2001;138:361–365.
    1. Mastretta E, et al. Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. J Pediatr Gastroenterol Nutr. 2002;35:527–531.
    1. Chouraqui JP, et al. Acidified milk formula supplemented with bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr. 2004;38:288–292.
    1. Thibault H, et al. Effects of long-term consumption of a fermented infant formula (with bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr. 2004;39:147–152.
    1. Pawlowski SW, et al. Diagnosis and treatment of acute or persistent diarrhea. Gastroenterology. 2009;136:1874–1886.
    1. Shamir R, et al. Evaluation of a diet containing probiotics and zinc for the treatment of mild diarrheal illness in children younger than one year of age. J Am Coll Nutr. 2005;24:370–375.
    1. Isolauri E, et al. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics. 1991;88:90–97.
    1. Shornikova AV, et al. A trial in the Karelian Republic of oral rehydration and LactobacillusGG for treatment of acute diarrhoea. Acta Paediatr. 1997;86:460–465.
    1. Guarino A, et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr. 1997;25:516–519.
    1. Guandalini S, et al. LactobacillusGG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30:54–60.
    1. Shornikova AV, et al. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J. 1997;16:1103–1107.
    1. Szajewska H, et al. Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children. Benef Microbes. 2014;5:285–293.
    1. Simakachorn N, et al. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr. 2000;30:68–72.
    1. Szymanski H, et al. Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains—a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;23:247–253.
    1. Costa-Ribeiro H, et al. Limitations of probiotic therapy in acute, severe dehydrating diarrhea. J Pediatr Gastroenterol Nutr. 2003;36:112–115.
    1. Salazar-Lindo E, et al. Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048] BMC Pediatr. 2004;4:18.
    1. Kowalska-Duplaga K, et al. Efficacy of Trilacin the treatment of acute diarrhoea in infants and young children—a multicentre, randomized, double-blind placebo-controlled study. Pediatria Współczesna. 2004;3:295–299.
    1. Khanna V, et al. Efficacy of tyndalized Lactobacillus acidophilus in acute diarrhea. Indian J Pediatr. 2005;72:935–938.
    1. Sarker SA, et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics. 2005;116:e221–e228.
    1. Huang JS, et al. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci. 2002;47:2625–2634.
    1. Van Niel CW, et al. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. 2002;109:678–684.
    1. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr. 2001;33(Suppl 2):S17–S25.
    1. Allen SJ, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;(11):CD003048. doi:10.1002/14651858.CD003048.pub3.
    1. Höchter W, et al. Saccharomyces boulardii bei akuter Erwachsenendiarrhoe. Münch Med Wschr. 1990;132:188–192.
    1. Cetina-Sauri G, Sierra Basto G. Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Ann Pediatr. 1994;41:397–400.
    1. Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr. 2005;94:44–47.
    1. Villarruel G, et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr. 2007;96:538–541.
    1. Castañeda C, et al. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Rev Mex Pueric Pediatr. 1995;2:12–16.
    1. Mansour-Ghanaei F, et al. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol. 2003;9:1832–1833.
    1. Saint-Marc T, et al. Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS. Ann Med Interne (Paris) 1991;142:64–65.
    1. Billoo AG, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol. 2006;12:4557–4560.
    1. Gutierrez Castrellon P, et al. An evidence based Iberic-Latin American guideline for acute gastroenteritis management in infants and prescholars. An Pediatr (Barc) 2010;72:220 e1–20.
    1. National Collaborating Centre for Women’s and Children’s Health. Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment and management in children younger than 5 years. National Institute for Health and Clinical Excellence (NICE). 2009. Accessed 30 Oct 2014.
    1. WGO. Probióticos y Prebióticos. World Gastroenterology Organisation. 2011. . Accessed 30 Oct 2014.
    1. Sazawal S, et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;6:374–382.
    1. Francavilla R, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea—a double-blind study. Aliment Pharmacol Ther. 2012;36:363–369.
    1. Turck D, et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37:22–26.
    1. Szajewska H, et al. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr. 2006;149:367–372.
    1. Advice for travelers. Treat Guidel Med Lett. 2004;2(21):33–40.
    1. Advice for travelers. Med Lett Drugs Ther. 1996;38(969):17–20.
    1. Mackell S. Traveler’s diarrhea in the pediatric population: etiology and impact. Clin Infect Dis. 2005;41(Suppl 8):S547–S552.
    1. Hilton E, et al. Efficacy of LactobacillusGG as a diarrheal preventive in travelers. J Travel Med. 1997;4:41–43.
    1. Katelaris PH, et al. Lactobacilli to prevent traveler’s diarrhea? N Engl J Med. 1995;333:1360–1361.
    1. Oksanen PJ, et al. Prevention of travellers’ diarrhoea by LactobacillusGG. Ann Med. 1990;22:53–56.
    1. Kollaritsch H, et al. Prevention of traveler’s diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Fortschr Med. 1993;111:152–156.
    1. Boonyaritichaikij S, et al. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. Helicobacter. 2009;14:202–207.
    1. Cruchet S, et al. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition. 2003;19:716–721.
    1. Gotteland M, et al. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr. 2005;94:1747–1751.
    1. Szajewska H, et al. Randomized, double-blind, placebo-controlled trial: effect of LactobacillusGG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48:431–436.
    1. Sykora J, et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol. 2005;39:692–698.
    1. Goldman CG, et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition. 2006;22:984–988.
    1. Lionetti E, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther. 2006;24:1461–1468.
    1. Sýkora J, et al. Supplements of one week triple drug therapy with special probiotic Lactobacillus casei imunitass (Strain DN-114 000) and Streptococcus thermophilus and Lactobacillus bulgaricus in the eradication of H. pylori-colonized children: a prospective randomised trial [abstract P0900] J Pediatr Gastroenterol Nutr. 2004;39:S400.
    1. Hurduc V, et al. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr. 2009;98:127–131.
    1. Hyman PE, et al. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2006;130:1519–1526.
    1. Savino F. Focus on infantile colic. Acta Paediatr. 2007;96:1259–1264.
    1. Metcalf TJ, et al. Simethicone in the treatment of infant colic: a randomized, placebo-controlled, multicenter trial. Pediatrics. 1994;94:29–34.
    1. Akcam M, Yilmaz A. Oral hypertonic glucose solution in the treatment of infantile colic. Pediatr Int. 2006;48:125–127.
    1. Danielsson B, Hwang CP. Treatment of infantile colic with surface active substance (simethicone) Acta Paediatr Scand. 1985;74:446–450.
    1. Gupta SK. Update on infantile colic and management options. Curr Opin Investig Drugs. 2007;8:921–926.
    1. Savino F, et al. A randomized double-blind placebo-controlled trial of a standardized extract of Matricariae recutita, Foeniculum vulgare and Melissa officinalis (ColiMil) in the treatment of breastfed colicky infants. Phytother Res. 2005;19:335–340.
    1. Anabrees J, et al. Probiotics for infantile colic: a systematic review. BMC Pediatr. 2013;13:186.
    1. Szajewska H, et al. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;162:257–262.
    1. Savino F, et al. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics. 2007;119:e124–e130.
    1. Savino F, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126:e526–e533.
    1. Chau K, et al. Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr. 2015;166(74–8):e1.
    1. Savino F, et al. Preventive effects of oral probiotic on infantile colic: a prospective, randomised, blinded, controlled trial using Lactobacillus reuteri DSM 17938. Benef Microbes. 2014:1–7. [Epub ahead of print].
    1. Indrio F, et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. JAMA Pediatr. 2014;168:228–233.
    1. Sung V, et al. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ. 2014;348:g2107.
    1. Saavedra JM, et al. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr. 2004;79:261–267.
    1. Fernandez JI, De las Cuevas T. Enterocolitis necrotizante neonatal. Bol Pediatr. 2006;46:172–178.
    1. Deshpande G, et al. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet. 2007;369:1614–1620.
    1. Samanta M, et al. Prophylactic probiotics for prevention of necrotizing enterocolitis in very low birth weight newborns. J Trop Pediatr. 2009;55:128–131.
    1. Millar M, et al. Probiotics for preterm infants? Arch Dis Child Fetal Neonatal Ed. 2003;88:F354–F358.
    1. Mattar AF, et al. Effect of probiotics on enterocyte bacterial translocation in vitro. Pediatr Surg Int. 2001;17:265–268.
    1. Orrhage K, Nord CE. Factors controlling the bacterial colonization of the intestine in breastfed infants. Acta Paediatr. 1999;88:47–57.
    1. Reid G, et al. Can bacterial interference prevent infection? Trends Microbiol. 2001;9:424–428.
    1. Duffy LC. Interactions mediating bacterial translocation in the immature intestine. J Nutr. 2000;130:432S–436S.
    1. Martin CR, Walker WA. Probiotics: role in pathophysiology and prevention in necrotizing enterocolitis. Semin Perinatol. 2008;32:127–137.
    1. Schanler RJ. Probiotics and necrotising enterocolitis in premature infants. Arch Dis Child Fetal Neonatal Ed. 2006;91:F395–F397.
    1. Alfaleh K, Bassler D. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2008;(1):CD005496. doi:10.1002/14651858.CD005496.pub2..
    1. Bin-Nun A, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147:192–196.
    1. Lin HC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005;115:1–4.
    1. Wolvers D, et al. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr. 2010;140:698S–712S.
    1. Alfaleh K, et al. Probiotics reduce the risk of necrotizing enterocolitis in preterm infants: a meta-analysis. Neonatology. 2010;97:93–99.
    1. Deshpande G, et al. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125:921–930.
    1. Hunter C, et al. Effect of routine probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight <1000 grams: a sequential analysis. BMC Pediatr. 2012;12:142.
    1. Kadowaki N, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863–869.
    1. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620–1633.
    1. Bousvaros A, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis. 2005;11:833–839.
    1. Day AS, et al. Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease. J Paediatr Child Health. 2004;40:681–684.
    1. Miele E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–443.
    1. Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2008;20(Suppl 1):121–129.
    1. Drossman DA, Dumitrascu DL, Rome III. New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15:237–241.
    1. Karantanos T, et al. Current insights in to the pathophysiology of Irritable Bowel Syndrome. Gut Pathog. 2010;2:3.
    1. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005;147:197–201.
    1. Gawronska A, et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25:177–184.
    1. Guandalini S, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51:24–30.
    1. Banaszkiewicz A, Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr. 2005;146:364–369.
    1. Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenterol. 2010;16:69–75.
    1. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol. 1997;99:179–185.
    1. Isolauri E, et al. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000;30:1604–1610.
    1. Kalliomaki M, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357:1076–1079.
    1. Kalliomaki M, et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361:1869–1871.
    1. Kukkonen K, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2007;119:192–198.
    1. Taylor AL, et al. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol. 2007;119:184–191.
    1. Rosenfeldt V, et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr. 2004;145:612–616.
    1. Kendler M, et al. Comparison of fecal microflora in children with atopic eczema/dermatitis syndrome according to IgE sensitization to food. Pediatr Allergy Immunol. 2006;17:141–147.
    1. Brouwer ML, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy. 2006;36:899–906.
    1. Sistek D, et al. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? Clin Exp Allergy. 2006;36:629–633.
    1. Viljanen M, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005;60:494–500.
    1. Rosenfeldt V, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol. 2003;111:389–395.
    1. Osborn DA, Sinn JK. Prebiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;(4):CD006474.
    1. Petroczi A, et al. Mission impossible? Regulatory and enforcement issues to ensure safety of dietary supplements. Food Chem Toxicol. 2011;49:393–402.
    1. Temmerman R, et al. Identification and antibiotic susceptibility of bacterial isolates from probiotic products. Int J Food Microbiol. 2003;81:1–10.
    1. Elliot E, Teversham K. An evaluation of nine probiotics available in South Africa, August 2003. S Afr Med J. 2004;94:121–124.
    1. Ibnou-Zekri N, et al. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infect Immun. 2003;71:428–436.
    1. Braegger C, et al. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr. 2011;52:238–250.
    1. Henker J, et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J. 2008;27:494–499.
    1. Yameen MA, et al. Nasal and perirectal colonization of vancomycin sensitive and resistant enterococci in patients of paediatrics ICU (PICU) of tertiary health care facilities. BMC Infect Dis. 2013;13:156.
    1. Bernet MF, et al. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut. 1994;35:483–489.
    1. Juntunen M, et al. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol. 2001;8:293–296.
    1. Urban MF, et al. Growth of infants born to HIV-infected women when fed a biologically acidified starter formula with and without probiotics. South Afr J Clin Nutr. 2008;21:28–32.
    1. Weizman Z, Alsheikh A. Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study. J Am Coll Nutr. 2006;25:415–419.
    1. Gibson RA, et al. Safety of supplementing infant formula with long-chain polyunsaturated fatty acids and Bifidobacterium lactis in term infants: a randomised controlled trial. Br J Nutr. 2009;101:1706–1713.
    1. Probiotics. Med Lett Drugs Ther. 2007;49(1267):66–8.
    1. Snydman DR. The safety of probiotics. Clin Infect Dis. 2008;46(Suppl 2):S104-11 (discussion S44–51).
    1. Broughton RA, et al. Neonatal meningitis due to Lactobacillus. Pediatr Infect Dis. 1983;2:382–384.
    1. Kunz AN, et al. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004;38:457–458.
    1. Perapoch J, et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis. 2000;19:468–470.
    1. Thompson C, et al. Lactobacillus acidophilus sepsis in a neonate. J Perinatol. 2001;21:258–260.
    1. Borriello SP, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36:775–780.
    1. Karpa KD. Probiotics for Clostridium difficile diarrhea: putting it into perspective. Ann Pharmacother. 2007;41:1284–1287.
    1. Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol. 2004;20:146–155.
    1. Mackay AD, et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect. 1999;5:290–292.
    1. Rautio M, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis. 1999;28:1159–1160.
    1. Cabana MD, et al. Probiotics in primary care pediatrics. Clin Pediatr (Phila) 2006;45:405–410.
    1. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis. 2005;41:1559–1568.
    1. Cassone M, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol. 2003;41:5340–5343.
    1. Jijon H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004;126:1358–1373.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit